DUBLIN--(BUSINESS WIRE)--The "Biopsy Devices Pipeline Insight and Competitive Landscape, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
The Biopsy Devices - Pipeline Insight and Competitive Landscape, 2020, report provides comprehensive insights about 20+ companies and 23+ pipeline devices in biopsy devices pipeline landscape.
Significant increase in incidence of cancer, such as breast, prostate, and lung, and rapid technological advancements such as 3D optical biopsies, MRI-targeted biopsies, and Ultrasound-guided biopsies fuel the adoption of biopsy devices. Moreover, rise in awareness on diagnosis of chronic diseases fosters the demand for integrated biopsy technologies such as stereotactic-guided biopsy.
This reports provides a detailed study of the emerging biopsy devices along with competitive landscape to help better understand the market.
Biopsy Devices Competitive Assessment
This segment of the biopsy devices pipeline report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including the latest news and press releases. The report also provides list of major players involved in the pipeline product development.
Product Type
Biopsy devices pipeline report is segmented based on product type such as core biopsy devices, aspiration biopsy needles and vacuum assisted biopsy devices.
Product Technique
Based on the technology biopsy devices are of various types:
1. Ultrasound-guided Biopsy
2. Stereotactic-guided Biopsy
3. MRI-guided Biopsy
The biopsy device pipeline assessment covers the entire types of these techniques.
Product Application
The biopsy devices are used in breast biopsy, lung biopsy, colorectal biopsy and prostate biopsy.
Major Players in Biopsy Devices
There are approx. 20+ key companies which are developing the products for biopsy devices.
3D Biopsy Device: 3DBiopsy, Inc.
3DBiopsy is developing a new variable biopsy device, capable of taking a prostate specimen up to 2 to 5 cm in length, along with a biopsy needle that retrieves over 90% of the tissue sampled. The current biopsy devices take short (average 12 mm) fragmented specimens which miss cancers in 30% and mischaracterize the tumor aggressiveness in up to 50%. Patients undergoing MRI targeted fusion biopsy also require additional sampling due to the inadequacy of the shorter specimens. The Company's device will sample both peripheral and anterior zones and is capable of completely encompassing regions of interest when MRI fusion is performed.
The OsteoAccess System: ActuatedMedical
Actuated Medical developed the OsteoAccess System to assist clinicians in bone marrow biopsy and aspiration procedures. The System uses controlled, micron-scale needle vibration to reduce the penetration force enabling easier cortical bone access.
Biopsy Devices: Competitive Benchmarking
This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.
The analysis is based on
- Brand Positioning of Leading companies
- Application
- Industry Collaborations
Biopsy Devices: Commercialization Activity
This segment of the report provides a detailed list of any commercial activity in the field of biopsy devices ranging from collaboration, mergers and acquisition, recent breakthrough among others.
Development Activities
- In February 2019, University of Cambridge and Cambridge University Hospitals (CUH) researcher and urologist developed the CamProbe as a prototype to take safer prostate biopsies. The device is in the clinical stage.
- In June, 2019 the first of its kind virtual biopsy devices has been created by Rutgers University scientist. It uses sound vibrations and pulses of near-infrared light that can quickly determine a skin lesion's depth and potential malignancy without using a scalpel.
Biopsy Devices: Reimbursement
Since January 2003, Medicare covers percutaneous image-guided breast biopsy using stereotactic or ultrasound imaging for a radiographic abnormality that is nonpalpable and is graded as a BIRADS III, IV, or V. Palpable Breast Lesions Effective January 1, 2003, Medicare covers percutaneous image guided breast biopsy using stereotactic or ultrasound imaging for palpable lesions that are difficult to biopsy using palpation alone.
Companies Mentioned
- 3DBiopsy Inc
- Actuated Medical Inc
- Arch Medical Devices Ltd
- Boston Scientific Corp
- C. R. Bard Inc
- CleveX, Inc.
- Control Medical Technology LLC
- Crux Medical Innovations
- Data Driven Diagnostic Sciences Inc
- Dune Medical Devices Ltd
- Endoscopic Assist Devices LLC
- LX Medical Corp
- MI4 Spine, LLC
- MRI Interventions Inc
- Promaxo Inc
- Quality ElectroDynamics LLC
- Vascular BioSciences
- Verisante Technology Inc
- VitruMed Inc.
- Zamar Care
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/16gf56
